| Literature DB >> 20369074 |
Abstract
Selective antagonism of centrally localized histamine H(3) receptors has been shown to enhance the release of a wide spectrum of important neurotransmitters including acetylcholine, gamma-aminobutyric acid, dopamine and noradrenalin, among others, which play fundamental roles in cognitive processes, in an output-dependent manner. The cognitive-enhancing effects of H(3) receptor antagonists across multiple cognitive domains in a wide number of preclinical cognition models also endow confidence in this therapeutic strategy for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder and the cognitive deficits often expressed in schizophrenia. Recent positive clinical reports are beginning to reinforce this optimism. Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20369074 DOI: 10.1358/dnp.2010.23.2.1475899
Source DB: PubMed Journal: Drug News Perspect ISSN: 0214-0934